Urology Times staff

In this episode, Samuel J. Peretsman, MD, discusses how to get started with HIFU for prostate cancer and performing robotic prostatectomy following HIFU.

Amanda North, MD, outlines finding from a paper recently published in Urology Practice.

In this episode, Samuel J. Peretsman, MD, explains what he tells patients undergoing HIFU to expect postoperatively.

In this episode, Samuel J. Peretsman, MD, describes his background and experience with HIFU as a treatment for patients with prostate cancer, and also discusses his treatment criteria for the modality.

In this episode, Angela B. Smith, MD, MS, of UNC Lineberger Comprehensive Cancer Center, discusses the recent FDA approval of Jelmyto, which is the first therapy for the treatment of low-grade upper tract urothelial cancer.

Urology-related FDA approvals from 2016 encompassed drugs and devices for prostate cancer, renal cell carcinoma, bladder cancer, stone disease, and more.

Bruce R. Kava, MD, presents the take home messages on BPH/LUTS from the AUA annual meeting in San Diego.

Mantu Gupta, MD, presents the take home messages on stone disease/endourology from the AUA annual meeting in San Diego.

Priya Padmanabhan, MD, MPH, presents the take home messages on female urology/incontinence/urodynamics from the AUA annual meeting in San Diego.

Danil V. Makarov, MD, MHS, presents the take home messages on outcomes analysis.

Edmund Chiong, MD, presents the take home messages on bladder cancer from the AUA annual meeting in San Diego.

Andrew Wagner, MD, presents the take home messages on kidney cancer from the AUA annual meeting in San Diego.

Jeannette M. Potts, MD, presents the take home messages on infection and inflammation at the AUA annual meeting in San Diego.

Data from a recent multicenter study provide new evidence that the beta-3 adrenoceptor agonist mirabegron (Myrbetriq) appears to be a viable alternative in patients with overactive bladder (OAB) who are poor responders to antimuscarinic agents or intolerant of their adverse events.

Men with symptomatic BPH had statistically significant, durable improvement in lower urinary tract symptoms (LUTS) following an office-based, minimally invasive prostatic urethral lift procedure, results of a pivotal randomized trial showed.

Stress incontinent women whose urinary urgency incontinence worsens following a sling procedure are a heterogeneous group, researchers report.

Mesh removal after suburethral sling procedures led to additional incontinence surgery in more than half of patients, including many who were continent prior to sling removal, a study of almost 100 patients showed.

Postmenopausal women may reduce their risk of incident kidney stone disease by engaging in physical activity and avoiding excessive caloric intake, analyses of data collected in the Women’s Health Initiative Observational Study show.

With rates of stone disease on the rise in the U.S., researchers have turned their attention to possible causes. New research exploring the possible influence of diabetes, diet, and even being a surgeon will be presented at the upcoming AUA annual meeting.

In the area of female urology, look for key studies at the AUA annual meeting involving sling surgery, onabotulinumtoxinA (Botox) injections, and reoperation after pelvic organ prolapse surgery with mesh.

The algorithm for urologists’ approach to male voiding symptoms is evolving, according to Steven A. Kaplan, MD, of Weill Cornell Medical College, New York. This will be evident in presentations on BPH and lower urinary tract symptoms at the AUA annual meeting.

As in adult urology, minimally invasive approaches continue to grow in pediatric urology, which is reflected in the research being presented at this year’s AUA annual meeting.

The newest urology products and services from Astellas Pharma US, Inc., Ethicon Endo-Surgery, Inc., Poiesis Medical, and Verathon Inc.

The newest urology products and services from Covidien, Beckman Coulter, Inc., Allergan Inc., the Seattle App Lab, and Griffin Technology.

Uroplasty, Inc. has announced that EmblemHealth now covers percutaneous tibial nerve stimulation using the company's Urgent PC Neuromodulation System for the treatment of overactive bladder and associated symptoms.

A new national survey shows severe physician shortages among certain pediatric specialties, and pediatric urologists top the list of those registering long wait times for pediatric surgical care.

R.D. Levin, MD, has joined Chesapeake Urology Associates and will see patients in the practice's Pine Heights Medical Center and Maple Lawn/Columbia offices in Maryland.

A recently developed genetic test to predict a man's risk for prostate cancer could reduce the need for repeat biopsies in men who have had a negative biopsy, data from a new study indicate.

Many men with prostate cancer do not need immediate treatment, especially if they have low PSA scores or low-risk tumors that are unlikely to grow and spread, according to a multicenter study that suggests such men who undergo radical prostatectomy fare no better than those undergoing observation.

New pediatric urology chiefs have been named at New York-Presbyterian/Morgan Stanley Children's Hospital, New York and the University of Wisconsin, Madison.